CSBR vs LEN · P/E 16, rev $56.9M vs rev $34.19B
Champions Oncology Inc (CSBR) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
Champions Oncology Inc (CSBR) is a biotechnology company listed on US.
LEN (LEN) common stock.
Latest reported CSBR revenue for 2025-04-30 was $56.9M. Net income was $4.7M. CSBR currently screens at market cap $99.8M and trailing P/E 16.0.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
CSBR currently screens at market cap $99.8M and trailing P/E 16.0. LEN currently screens at market cap $0.
Not investment advice. Open the CSBR and LEN stock pages for the full models.
Not investment advice.